In this randomized controlled study, individuals taking dolutegravir+darunavir/ritonavir had greater increases in systolic and diastolic blood pressure than those taking 2 nucleoside reverse-transcriptase inhibitors+darunavir/ritonavir at week-48. The difference remained significant after controlling for confounding factors, including weight gain.